Fig. 5
Risk ratios (a) and risk differences (b) for serious infections across RCTs in methotrexate-naive patients. Tofacitinib data are from the phase 3 ORAL Start study. BID twice daily, CI confidence interval, RCT randomized controlled trial, TNFi tumor necrosis factor inhibitors